KPS "Breast Cancer Treatment 'Neorings Tab' Surpasses 10 Billion KRW in Cumulative Sales"

The sales of ‘Neurings Tab’ (active ingredient: neratinib maleate), a breast cancer treatment drug sold by BigThink Therapeutics (hereinafter BigThink), a bio-subsidiary of KPS, have exceeded 10 billion KRW. It has been just over two years since its launch at the end of 2022.

On the 11th, KPS announced that the cumulative sales of the new breast cancer drug Neurings Tab surpassed 10 billion KRW as of the 2nd of this month. Neurings Tab recorded sales of 2.4 billion KRW in its first year of launch in 2022, followed by sales exceeding 5 billion KRW last year. This year, the number of prescriptions has steadily been maintained, showing solid sales volume.

Since its approval, Neurings Tab has passed the Drug Committee (DC) in a total of about 50 hospitals nationwide, including the Big 5 general hospitals such as Seoul National University, Asan, Samsung Seoul, Severance, and Seoul St. Mary’s, and is currently prescribed in more than 30 hospitals.

Neurings Tab is an oral epidermal growth factor receptor (HER2) positive breast cancer treatment developed by the US company Puma Biotechnology, which BigThink introduced domestically and received approval from the Ministry of Food and Drug Safety in October 2022.

The approved indication is as an adjuvant therapy after surgery for early breast cancer patients who are HER2 receptor positive and hormone receptor positive. It is the only anticancer treatment option that can reduce the risk of recurrence and brain metastasis in patients treated with trastuzumab (product name Herceptin)-based therapy. HER2-positive breast cancer frequently causes brain metastasis, and it is known that using Neurings Tab reduces the probability of brain metastasis to one-third. Neurings is recommended as an early breast cancer treatment in the clinical guidelines of the Korean Breast Cancer Society and the National Comprehensive Cancer Network (NCCN) in the United States.

In April this year, BigThink signed a mutual co-promotion contract with Boryung (formerly Boryung Pharmaceutical) for two breast cancer treatments including Neurings Tab and has been strengthening sales and marketing activities.

Following Neurings, BigThink’s Asia distribution rights for the topical solution for managing oral mucositis in cancer patients, ‘Mucosamin (MUCOSAMIN®),’ recorded sales of 90 million KRW in its first year last year, and this year alone, it has achieved sales of 256 million KRW domestically up to November, showing nearly triple growth.

Kim Ha-yong, CEO of BigThink Therapeutics, said, “We will continue to expand our portfolio mainly with overseas pharmaceuticals that have no domestic substitutes.” He added, “With active sales activities, we expect to achieve annual sales of 10 billion KRW by 2025.”

This content was produced with the assistance of AI translation services.